Target intelligence / Profile preview

SLC8A1 antisense RNA 1 (SLC8A1-AS1)

Target
SLC8A1-AS1
Molecular classification
Other, non-coding RNA, antisense RNA
01

Overview

SLC8A1 antisense RNA 1 (SLC8A1-AS1) is an uncharacterized non-coding RNA gene, annotated as such in the Ensembl database with gene ID ENSG00000252473[7]. It is classified as an antisense transcript at the SLC8A1 locus, but as of now, no published data demonstrates that it functions as a protein, drug target, or biomarker. There is no evidence it encodes a protein or plays a disease-relevant or druggable biological role[1][7].

02

Biological functions

Unknown

Beyond the preview

Go deeper on SLC8A1 antisense RNA 1 (SLC8A1-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLC8A1 antisense RNA 1 (SLC8A1-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call